OR WAIT null SECS
April 06, 2022
FDA has granted an expanded Emergency Use Authorization to Pfizer and BioNTech’s COVID-19 vaccine boosters in individuals aged 50 years and older.
March 25, 2022
Pfizer’s respiratory syncytial virus vaccine candidate has received Breakthrough Therapy Designation from FDA for the prevention of RS in older adults.
March 21, 2022
AstraZeneca’s antibody combination has been authorized for use in Great Britain to prevent COVID-19 in high-risk populations and people for whom vaccination may not be effective.
Moderna has reached an agreement with the Ministry of Health, Labor, and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of its COVID-19 Booster Vaccine.
physIQ and CellCarta are conducting a study to evaluate individual patient response to vaccination using wearable biosensors.
March 16, 2022
EMA has recommended that possible side effects of Spikevax and Janssen COVID-19 vaccines be added to product information.
NIH has launched one of the first Phase 1 clinical trials to examine mRNA technology for HIV.
March 08, 2022
Johnson & Johnson have announced a landmark agreement to enable the manufacturing and availability of its COVID-19 vaccine in Africa by an African company.
Moderna has announced that it has entered a Memorandum of Understanding with the government of the Republic of Kenya to establish its first mRNA manufacturing facility in Africa.
March 04, 2022
Evonik has increased its global supply of plant-derived cholesterol used for mRNA vaccines and gene therapies.